ColemanRE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev2001; 27: 165–176.
2.
ColemanRE. Skeletal complications of malignancy. Cancer1997; 80(Suppl 8): 1588–1594.
3.
PfeilschifterJ., DielIJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol2000; 18: 1570–1593.
4.
HillnerB.E., IngleJ.N., ChlebowskiR.T.American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol2003; 21: 4042–4057. Erratum in: J Clin Oncol 2004; 22: 1351.
5.
RogersM.J., GordonS., BenfordH.L.Cellular and molecular mechanisms of action of bisphosphonates. Cancer2000; 88(Suppl 12): 2961–2978.
6.
FisherJ.E., RodanG.A., ReszkaAA. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology2000; 141: 4793–4796.
7.
SietsemaW.K., EbetinoF.H., SalvagnoA.M.Antiresorptive dose-response relationship across three generations of bisphosphonates. Drugs Exp Clin Res1989; 15: 389–396.
8.
DumonJ.C., JournéF., KheddoumiN.Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol2004; 45: 521–529.
9.
JagdevS.P., ColemanR.E., ShipmanC.M.The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer2001; 84: 1126–1134.
10.
UllénA., LennartssonL., Hjelm-ErikssonM.Additive/synergistic anti-tumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronate [poster]. Presented at the European Winter Oncology Conference (EWOC-8), January 19-24, 2003, Flims, Switzerland.
11.
Neville-WebbeH., Rostami-HodjeganA., EvansC.A.Sequence and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer2005; 113: 364–371.
12.
FournierP., BoissierS., FilleurS.'Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res2002; 62: 6538–6544.
13.
WoodJ., BonjeanK., RuetzS.Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther2002; 302: 1055–1061.
14.
JohnsonJ.R., WilliamsG., PazdurR.End points and United States Food and Drug Administration Approval of Oncology Drugs. J Clin Oncol2003; 21: 1404–1411.
15.
RosenL.S., GordonD., KaminskiM.Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer2003; 98: 1735–1744.
16.
MajorP.P., CookR.J., ChenB.L.Survival-adjusted cumulative event analysis of skeletal-related events in patients with cancer metastatic to bone in trials of zoledronic acid. Presented at What is new in bisphosphonates? Seventh workshop on bisphosphonates - from the laboratory to the patient, March 24-26, 2004, Davos, Switzerland.
17.
KohnoN., AogiK., MinamiH.Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol2005; 23: 3314–3321.
18.
LiptonA., TheriaultR.L., HortobagyiG.N.Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer2000; 88: 1082–1090.
19.
BodyJ.J., DielI.J., LichinitserM.R.Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol2003; 14: 1399–1405.
20.
BodyJ.J., DielI.J., LichinitzerM.Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer2004; 90: 1133–1137.
21.
PavlakisN., StockierM.Bisphosphonates for breast cancer (Cochrane Review). In: The Cochrane Library, Issue 1.Hoboken, NJ: John Wiley and Sons, Ltd, 2004.
22.
PatersonA.H., PowlesT.J., KanisJ.A.Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol1993; 11: 59–65.
23.
DielI.J., BodyJ.J., LichinitserM.R.Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer2004; 40: 1704–1712.
24.
StephensJ.M., AaproM.S., BottemanM.F.A Markov model to evaluate the cost effectiveness of intravenous (IV) zoledronic acid vs IV generic pamidronate or oral ibandronate in the prevention of bone complications in breast cancer patients with bone metastases. Proc Am Soc Clin Oncol2005; abs 664.
